• 1
    Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Pub Health 1998;88: 133742.
  • 2
    Clark CM, Trojanowski JQ, eds. Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. New York: McGraw-Hill, 2000.
  • 3
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington: The Association, 1994.
  • 4
    Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA 1997;278: 136371.
  • 5
    McKhann G, Drachman D, Folstein M, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34: 93944.
  • 6
    Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56: 114353.
  • 7
    Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000; 41: 19208.
  • 8
    Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000;343: 4506.
  • 9
    Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286: 21207.
  • 10
    Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97: 603742.
  • 11
    Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56: 115466.
  • 12
    Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57: 4818.
  • 13
    National Institute on Aging National Institutes of Health. Progress Report on Alzheimer's Disease, 2000: Taking the Next Steps [Internet]. Washington: The Institute, 2000. Available from:
  • 14
    Gurwitz D. Immunization for Alzheimer's disease: yet closer to clinical trials. Trends Mol Med 2001;7: 385.
  • 15
    Scinto LF, Daffner KR, eds. Early Diagnosis of Alzheimer's Disease. Totowa (NJ): Humana Press, 2000.
  • 16
    Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol 2001;58: 397405.
  • 17
    Petersen RC, Stevens JC, Ganguli M, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56: 113342.
  • 18
    Willmer J, Mohr E. Evaluation of selection criteria used in Alzheimer's disease clinical trials. Can J Neurol Sci 1998;25: 3943.
  • 19
    McMahon PM, Araki SS, Neumann PJ,  et al. Cost-effectiveness  of  functional  imaging  tests  in the diagnosis of Alzheimer disease. Radiology 2000;217: 5868.
  • 20
    Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 1996;46: 64150.
  • 21
    Mohs RC, Breitner JC, Silverman JM, Davis KL. Alzheimer's disease: morbid risk among first-degree relatives approximates 50% by 90 years of age. Arch Gen Psychiatry 1987;44: 4058.
  • 22
    Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer's disease. JAMA 2002;287: 32936.
  • 23
    Matchar DM, Kulasingam SL, McCrory DC, et al. Use of Positron Emission Tomography and Other Neuroimaging Techniques in the Diagnosis and Management of Alzheimer's Disease and Dementia [Internet]. Prepared for the Agency for Healthcare Policy and Research Contract No. 290-97-0014, Task Order 7. Durham (NC): Duke Evidence-Based Practice Center, Center for Health Policy Research, 2001 Dec 14. Available from:
  • 24
    Ballard C, O'Brien J, Morris CM, et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatric Psychiatry 2001;16: 499503.
  • 25
    Patwardhan M, McCrory DC, Matchar DB, et al. The operating characteristics of PET in the diagnosis and management of AD. Radiology 2003;in press.
  • 26
    Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 27
    Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 1999;37: 2732.
  • 28
    Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med 2000;132: 9337.
  • 29
    O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999;47: 5708.
  • 30
    Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov Model. Clin Ther 1999;21: 123040.
  • 31
    Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52: 113845.
  • 32
    Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43: 25366.
  • 33
    Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980;302: 110917.